Effects of Unbound Mycophenolic Acid on Inosine Monophosphate Dehydrogenase Inhibition in Pediatric Kidney Transplant Patients

被引:14
|
作者
Smits, Thomas A. [1 ]
Cox, Shareen [1 ]
Fukuda, Tsuyoshi [1 ,2 ]
Sherbotie, Joseph R. [3 ]
Ward, Robert M. [3 ]
Goebel, Jens [2 ,4 ]
Vinks, Alexander A. [1 ,2 ]
机构
[1] Cincinnati Childrens Hosp Med Ctr, Div Clin Pharmacol, Cincinnati, OH 45229 USA
[2] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA
[3] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA
[4] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA
关键词
mycophenolic acid; inosine monophosphate dehydrogenase; pediatric kidney transplant; free concentration; PK/PD; PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIP; RENAL-TRANSPLANTATION; PROTEIN-BINDING; RECIPIENTS; MOFETIL; ALBUMIN; CHILDREN; ASSAY;
D O I
10.1097/FTD.0000000000000081
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Mycophenolic acid (MPA) is a key immunosuppressive drug that acts through inhibition of inosine monophosphate dehydrogenase (IMPDH). MPA is commonly measured, as part of therapeutic drug monitoring, as the total concentration in plasma. However, it has been postulated that the free (unbound) fraction of MPA (fMPA) is responsible for the immunosuppressive effects. In this study, a sensitive low volume high-performance liquid chromatography (HPLC) assay was developed to measure fMPA concentrations to explore the relationship between fMPA and IMPDH activity. Methods: To obtain fMPA concentrations, plasma samples were filtrated using Centrifree ultrafiltration devices. The ultrafiltrate was analyzed by HPLC using a Kinetex C18 column (2.6 mu m, 3.0 x 75 mm). fMPA concentrations were compared with the total MPA concentrations available in 28 pediatric kidney transplant patients at 3 consecutive occasions after transplantation. The relationship between fMPA and IMPDH activity was analyzed using an E-max model. Results: The HPLC assay, using 25 mu L of the ultrafiltrates, was validated over a range from 2.5 to 1000 mu L with good accuracy, precision, and reproducibility. Total and free MPA concentrations were well correlated (R-2 = 0.85, P < 0.0001), although large intraindividual and interindividual variability in the bound MPA fractions was observed. The overall relationship between fMPA concentrations and IMPDH inhibition using the Emax model was comparable with that of total MPA, as previously reported. The model estimated EC50 value (164.5 mu L) is in good agreement with reported in vitro EC50 values. Conclusions: This study provides a simple HPLC method for the measurement of fMPA and a pharmacologically reasonable EC50 estimate. The good correlation between the total and free MPA concentrations suggests that routine measurement of fMPA to characterize mycophenolate pharmacokinetic and pharmacodynamic does not seem warranted, although the large variability in the bound fractions of MPA warrants further study.
引用
收藏
页码:716 / 723
页数:8
相关论文
共 50 条
  • [1] The Effects of Unbound Mycophenolic Acid (MPA) on Inosine Monophosphate Dehydrogenase (IMPDH) Inhibition in Pediatric Kidney Transplant Patients
    Smits, T.
    Cox, S.
    Fukuda, T.
    Vinks, A.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 683 - 683
  • [2] Inosine monophosphate dehydrogenase activity as biomarker of mycophenolic acid exposure in pediatric kidney transplant recipients
    Goebel, Jens
    Thogersen, Havard
    Cox, Shareen
    Maseck, Denise
    Logan, Barbara
    Sherbotie, Joseph R.
    Vinks, Alexander A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 369 - 370
  • [3] Monitoring of inosine monophosphate dehydrogenase (IMPDH) as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients
    Thogersen, Havard
    Goebel, Jens
    Cox, Shareen
    Maseck, Denise
    Logan, Barbara
    Vinks, Alexander A.
    THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 479 - 480
  • [4] Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients
    Fukuda, Tsuyoshi
    Goebel, Jens
    Thogersen, Havard
    Maseck, Denise
    Cox, Shareen
    Logan, Barbara
    Sherbotie, Joseph
    Seikaly, Mouin
    Vinks, Alexander A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (03): : 309 - 320
  • [5] Pharmacokinetic-pharmacodynamic modeling of the effect of mycophenolic acid exposure on inosine monophosphate dehydrogenase activity in pediatric kidney transplant patients
    Thogersen, Havard
    Goebel, Jens
    Cox, Shareen
    Maseck, Denise
    Logan, Barbara
    Vinks, Alexander A.
    THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 480 - 480
  • [6] Effect of mycophenolic acid on inosine monophosphate dehydrogenase (IMPDH) activity in liver transplant patients
    Neuberger, M.
    Sommerer, C.
    Boehnisch, S.
    Metzendorf, N.
    Mehrabi, A.
    Stremmel, W.
    Gotthardt, D.
    Zeier, M.
    Weiss, K. H.
    Rupp, C.
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2020, 44 (04) : 543 - 550
  • [7] Species specific inhibition of inosine 5′-monophosphate dehydrogenase by mycophenolic acid
    Digits, J
    Hedstrom, L
    FASEB JOURNAL, 1999, 13 (07): : A1353 - A1353
  • [8] Inosine monophosphate dehydrogenase activity as a biomarker of mycophemolic acid effects in pediatric kidney transplant recipients.
    Thogersen, H.
    Goebel, J.
    Cox, S.
    Maseck, D.
    Logan, B.
    Vinks, A. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S4 - S4
  • [9] Inosine monophosphate dehydrogenase activity as a biomarker of mycophemolic acid effects in pediatric kidney transplant recipients.
    Thogersen, H.
    Goebel, J.
    Cox, S.
    Maseck, D.
    Logan, B.
    Vinks, A. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S38 - S38
  • [10] Species-specific inhibition of inosine 5′-monophosphate dehydrogenase by mycophenolic acid
    Digits, JA
    Hedstrom, L
    BIOCHEMISTRY, 1999, 38 (46) : 15388 - 15397